Defining the risks of mesenchymal stromal cell therapy

Author(s):
Prockop, D.J.; Brenner, M.; Fibbe, W.E. (0000-0001-8539-9011); Horwitz, E.; Blanc, K. le; Phinney, D.G.; Simmons, P.J.; Sensebe, L.; Keating, A.
Published
2010
Publication type
Article / Letter to editor

Abstract

We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.

MSCs mesenchymal stem cells cell contamination stem-cells transformation culture fibroblasts senescence
Date issued
2010-12-31
Language
English
Is part of
Cytotherapy (2010), Vol. 12, no. 5, p. 576-578
hdl
1887/111623
doi
10.3109/14653249.2010.507330